Plastic and reconstructive surgeryDec 2, 2025

Nutritional Issues After Large Weight Loss Surgery: Advice for Plastic Surgeons on Weight-Loss Drugs and Stomach Surgery

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Jan 20, 2026

Abstract

Over 40% of U.S. adults are affected by obesity, increasing the need for effective nutritional strategies post-bariatric surgery.

Bariatric surgery leads to significant weight loss but can result in nutritional deficiencies, particularly in iron, B12, and protein.
Laparoscopic sleeve gastrectomy (LSG) has a lower risk of malabsorption compared to Roux-en-Y gastric bypass (RYGB) but still poses risks for nutrient deficiencies.
The use of GLP-1 receptor agonists, such as semaglutide and tirzepatide, may further decrease protein and micronutrient intake due to appetite suppression and delayed gastric emptying.
Many patients, especially those on GLP-1 medications, do not meet the recommended protein intake of 60-120 g/day, which is crucial for wound healing.
Nutritional strategies should focus on individualized protein timing and frequent small meals to enhance perioperative intake and correct micronutrient deficiencies.

Simplified

With obesity affecting over 40% of U.S. adults, bariatric surgery (BS) has become a cornerstone treatment, leading to massive weight loss (MWL) but also significant nutritional challenges. As demand for body contouring surgery (BCS) grows among post-BS patients, plastic surgeons must understand how evolving weight loss strategies, particularly the widespread use of GLP-1 receptor agonists and the shift to laparoscopic sleeve gastrectomy (LSG), impact nutritional status and wound healing. Unlike Roux-en-Y gastric bypass (RYGB), LSG presents fewer malabsorptive risks but still predisposes patients to deficiencies in iron, B12, and protein due to reduced intake and food intolerance.The rise of GLP-1 medications such as semaglutide and tirzepatide presents new considerations. These agents suppress appetite and delay gastric emptying, which can further reduce protein and micronutrient intake. For patients on GLP-1s undergoing BCS, nutritional strategies must be tailored to ensure adequate perioperative protein and caloric intake, emphasizing timing, such as spacing protein throughout the day and increasing intake through small, more frequent meals.Protein deficiency, which impairs collagen production, angiogenesis, and immunity, is a key risk factor for poor wound healing. Despite guidelines recommending 60-120 g/day of protein, many patients fall short, particularly those losing weight on GLP-1RAs. Perioperative nutritional optimization, including individualized protein timing plans, aggressive correction of micronutrient deficiencies, and supplementation strategies, is essential. This review provides comprehensive recommendations for plastic surgeons caring for MWL patients, including those using GLP-1RAs, to optimize surgical outcomes and minimize complications.

Full Text

Full text is available at the source.

View Full Text ↗

Funding

Competing interests

Disclosures: Dr. David Rometo reports the following potential conflicts of interest: 1) Served on an advisory board for Novo Nordisk regarding phase 3 trial data for Cagrilintide/Semaglutide combination therapy (this role began after the completion of this collaboration). 2) Paid consultant for Pennsylvania Health and Human Services on data analysis of Medicaid coverage of anti-obesity medications, including GLP-1 receptor agonists. All other authors have no relevant financial disclosures or conflicts of interest to declare.

PubMed

Nutritional Issues After Large Weight Loss Surgery: Advice for Plastic Surgeons on Weight-Loss Drugs and Stomach Surgery

Abstract

Full Text

Funding

Competing interests

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Funding

Competing interests

Related papers

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief